Vaccine News and Research

Latest Vaccine News and Research

GeoVax opens second HIV clinical trial site at Alabama Vaccine Research Clinic

GeoVax Labs, Inc., a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, announced today the opening of a second clinical trial site at the Alabama Vaccine Research Clinic (AVRC) of the University of Alabama at Birmingham (UAB) to expand the company's HIV therapeutic vaccine trial.

9 Feb 2011

Sartorius reports consolidated sales revenue of 659.3 million for fiscal 2010

Sartorius, a leading international laboratory and process equipment provider, successfully closed the year 2010. Sales revenue and earnings substantially surpassed the year-earlier figures. Financial guidance for the Group, which was raised during the course of 2010, was met and even exceeded for some targets.

From Sartorius 9 Feb 2011

Gates Foundation awards USF $5.45M for malaria research

The University of South Florida received $5.45 million in grants from the Bill & Melinda Gates Foundation. The first grant is to create advanced devices that mimic the human liver to better study the life cycle of the malaria parasite - particularly the elusive liver stage where the disease may be most vulnerable to attack.

9 Feb 2011

Scientists develop novel technique to detect disordered protein folding

A team of scientists from The Scripps Research Institute and the University of California, San Diego have developed a novel technique to observe previously unknown details of how folded structures are formed from an intrinsically disordered protein.

9 Feb 2011

Vical announces issuance of US patent for HSV-2 vaccine

Vical Incorporated announced today the issuance of U.S. Patent No. 7,879,339, assigned to Vical and the University of Washington, covering DNA vaccines for herpes simplex virus type 2.

9 Feb 2011

Babies born to HIV-infected mothers have lower antibody levels against bacterial infections

Babies whose mothers have HIV, but who are not HIV-infected themselves, are born with lower levels of specific proteins in their blood called antibodies, which fight infection, compared with babies not exposed to HIV, a new study has found.

9 Feb 2011

Medicago granted FDA clearance for clinical development of seasonal flu vaccine

Medicago Inc. a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced it has received Food and Drug Administration ("FDA") clearance for its phase I H1N1 influenza VLP vaccine candidate ("H1N1 vaccine") clinical trial in the United States.

9 Feb 2011

Anti-cancer shots for boys in the pipeline

The Pharmaceutical Benefits Advisory Committee (PBAC) is deciding on whether to include the human papillomavirus (HPV) vaccine, Gardasil in in the National Immunization Program for boys.

8 Feb 2011

Total flu cover with one shot

In a medical breakthrough, English scientists have developed a so-called “universal” vaccine to influenza - one that protects against all strains of the potentially deadly illness. This would do away with the need for a new vaccine each flu season they say. Seasonal flu affects up to 20 percent of the population and kills an average of 24,600 people each year. This vaccine would act against swine flu as well assure researchers.

8 Feb 2011

International research team receives AACR award for innovative, meritorious science

The Fifth Annual AACR Team Science Award will be given to a team of internationally renowned molecular biologists, epidemiologists, biostatisticians and clinicians from Fred Hutchinson Cancer Research Center and University of Washington who have worked together on human papillomavirus for more than 20 years.

8 Feb 2011

Elan 2010 total revenue increases 5% to $1,169.7 million

Elan Corporation, plc today reported its fourth quarter and full-year 2010 financial results and provided financial guidance for 2011.

8 Feb 2011

Anthem Blue Cross reminds seniors in Maine to get vaccinated against annual flu, pneumonia

While the seasonal flu can be very serious for patients of any age, senior citizens are particularly vulnerable. That's why Anthem Blue Cross and Blue Shield in Maine is reminding seniors across the state to get their annual flu and pneumonia vaccinations.

8 Feb 2011

New study shows economic burden of dengue in Western Hemisphere is $2.1 billion per year

Dengue illness, the most common mosquito-borne viral disease in the world, has expanded from its Southeast Asian origins and is resurgent in countries such as Argentina, Chile and the continental United States.

8 Feb 2011

Human Vaccines journal publishes paper on Inovio's new DNA vaccine delivery technology

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that its new generation DNA vaccine delivery technology, which provides the powerful enabling capabilities of electroporation without contacting the skin, is highlighted in a paper published in the scientific journal Human Vaccines.

7 Feb 2011

HPV vaccine can prevent 90% of genital warts in men: Study

The vaccine for human papillomavirus can prevent 90 percent of genital warts in men when offered before exposure to the four HPV strains covered by the vaccine, according to a new multi-center study led by H. Lee Moffitt Cancer Center and UCSF.

4 Feb 2011

Salk Institute receives $2.3 million CIRM grant for translational research on Parkinson's disease

The Salk Institute has been awarded a $2.3 million grant by the California Institute for Regenerative Medicine for translational research focusing on developing a novel stem cell based therapy for Parkinson's disease.

4 Feb 2011

Lampreys may have dual immune defense system similar to that of humans

Biologists have discovered that primitive, predatory lampreys have structures within their gills that play the same role as the thymus, the organ where immune cells called T cells develop in mammals, birds and fish.

4 Feb 2011

Merck reports GAAP net income of $861 million for 2010

Merck, known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the fourth quarter of $0.88, which excludes purchase accounting adjustments, restructuring costs and merger-related expenses.

4 Feb 2011

Study finds total cost of dengue illness in Americans to be $2.1 billion per annum

The first assessment of the total cost of dengue illness in the Americas reveals the economic burden to be approximately $2.1 billion per year, exceeding that from other viral illnesses including human papillomavirus and rotavirus.

4 Feb 2011

U.S. Patent Office issues Notice of Allowance to Antigen Express AE37 cancer vaccine

Generex Biotechnology Corporation, together with its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, announced today that Antigen Express has received a Notice of Allowance from the United States Patent Office relating to an application making augmentative pharmaceutical composition claims for the Antigen Express AE37 immunotherapeutic cancer vaccine.

4 Feb 2011